Cypherpunk Technologies Inc. Common Stock (CYPH) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with CYPH
Recent news

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
CYPH

Cypherpunk Technologies Stock Jumps Pre-Market After It Accumulates More Zcash
Cypherpunk Technologies Stock Jumps Pre-Market After It Accumulates More Zcash
CYPH
Technical indicators
- RSI 14
- 50.04
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.31
- MACD histogram
- -0.13
- SMA 50
- $2.18
- Price above SMA 50
- EMA 50
- $2.39
- Price above EMA 50
- SMA 200
- $1.16
- Price above SMA 200
- EMA 200
- $1.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
CYPH

Cypherpunk Technologies Stock Jumps Pre-Market After It Accumulates More Zcash
Cypherpunk Technologies Stock Jumps Pre-Market After It Accumulates More Zcash
CYPH
About Cypherpunk Technologies Inc. Common Stock
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas E. Onsi J.D. | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director | 1969 |
| Mr. Will McEvoy | Chief Investment Officer & Director | 1996 |
| Kevin Zhang | Head of Mining | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 50.04
- MACD 12/26/9
- 0.17
- EMA 9 of MACD
- 0.31
- MACD histogram
- -0.13
- SMA 50
- $2.18
- Price above SMA 50
- EMA 50
- $2.39
- Price above EMA 50
- SMA 200
- $1.16
- Price above SMA 200
- EMA 200
- $1.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $1.60
- Average
- $3.25
- High
- $4.90
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +94.7 | -2.7 |



